Edward Copelan, MD, FACP
Carolinas HealthCare System’s Levine Cancer Institute is expanding its hematology-oncology program, in an effort to give patients with aggressive types of blood cancer increased access to comprehensive treatment options.
The expansion includes a new hematologic malignancies unit that will open in January 2014. It will be the first of its kind, designed to treat adult blood and marrow transplant patients in the greater Charlotte region.
The unit will include:
The program’s expansion will also support the development of new research at the Institute. By the end of 2013, physicians are slated to enroll patients in at least four new clinical trials.
Belinda Avalos, MD
“The expansion and enhancement of our hematology-oncology program exemplifies how Levine Cancer Institute is constantly evolving and adapting to meet the growing needs of patients, so that they have access to the best care possible,” said Edward Copelan, MD, FACP, chairman of the department of hematologic oncology and blood disorders. “Our team of newly recruited outstanding blood cancer experts will work together to provide state-of-the-art care for patients closer to home, while also making significant strides in clinical research.”
Dr. Copelan, who was recruited from Cleveland Clinic in 2012, is overseeing the development of the program. He and Belinda Avalos, MD, vice chair of the department of hematologic oncology and blood disorders, recently had a large international study accepted by Blood, a leading hematology-oncology medical journal, which demonstrates the efficacy of a radiation-free treatment option for patients with acute myeloid leukemia undergoing transplantation. Under Dr. Copelan’s leadership, the Institute’s Leukemia, Lymphoma and Multiple Myeloma Program is managed by newly recruited and nationally renowned physicians: